article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

article thumbnail

Merck to support development of Orna’s circular RNA (oRNA) therapies

European Pharmaceutical Review

Newly synthesised oRNA molecules are more compactly packaged into custom LNPs, which Orna has engineered to target key tissues in the body. Orna’s proprietary oRNA technology creates circular RNAs from linear RNAs by self-circularisation. We look forward to working with the talented scientific and technical teams at Orna.”